Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward. (PubMed, Transl Oncol) - Sep 29, 2026 - "The phase 3 KEYVIBE-010 trial investigated adjuvant vibostolimab (anti-TIGIT) plus pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma. Pembrolizumab monotherapy remains a standard-of-care option in the adjuvant setting, though other established regimens (e.g., nivolumab, dabrafenib/trametinib) apply to specific subgroups. The trial highlights the need for active comparators, futility boundaries, and predictive biomarkers in future adjuvant immunotherapy studies."
IO biomarker • Journal • Melanoma • Oncology • Solid Tumor • TIGIT
|
|
Qinghua Ke; Shiqiong Zhou
|